Paper24254965
Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Khellaf M and 8 others. Am J Hematol, 2014. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Papers, record 24254965. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24254965
- Disease
- systemic lupus erythematosus207 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Antinuclear | Major topic |
| Antirheumatic Agents | Major topic |
| Hydroxychloroquine | Major topic |
| Purpura, Thrombocytopenic, Idiopathic | Major topic |
| Adolescent | |
| Adult | |
| Female | |
| Humans | |
| Lupus Erythematosus, Systemic | |
| Male | |
| Middle Aged | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Trials6
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01549184 | Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02444728 | Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE | Results | ClinicalTrials.gov | |
| NCT03229746 | Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia | Results | ClinicalTrials.gov | |
| NCT06479291 | The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP | Results | ClinicalTrials.gov | |
| NCT06479304 | The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP | Results | ClinicalTrials.gov | |
| NCT06479317 | The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP | Results | ClinicalTrials.gov |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42603197 | Antinuclear antibody titre and its dynamics predict autoimmune disease progression in adults with immune thrombocytopenia. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/42603197 | PubMed |
| 42266695 | Autophagy, NET formation, and inflammation crosstalk in thrombotic autoimmune diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/42266695 | PubMed |
| 41585259 | Comparison of the efficacy of thalidomide combined with low-dose rituximab and low-dose rituximab alone in the treatment of steroid-resistant/refractory adult patients with primary immune thrombocytopenia: an open-label trial. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41585259 | PubMed |
| 41569352 | Immune thrombocytopenia in patients with connective tissue disease. | Clin Rheumatol | 2026 | https://conductscience.org/library/papers/41569352 | PubMed |
| 41495809 | A study of clinical manifestations and associated factors in photosensitive patients with systemic lupus erythematosus. | Eur J Med Res | 2026 | https://conductscience.org/library/papers/41495809 | PubMed |
| 39719150 | Primary versus Secondary Immune Thrombocytopenia (ITP): A Meeting Report from the 2023 McMaster ITP Summit. | Thromb Haemost | 2025 | https://conductscience.org/library/papers/39719150 | PubMed |
| 39627479 | Immune thrombocytopenia in patients with systemic lupus erythematosus. | Clin Rheumatol | 2025 | https://conductscience.org/library/papers/39627479 | PubMed |
| 39374586 | Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia. | Blood Adv | 2024 | https://conductscience.org/library/papers/39374586 | PubMed |
| 38916764 | Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse. | Clin Rheumatol | 2024 | https://conductscience.org/library/papers/38916764 | PubMed |
| 36969501 | Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia. | Ther Adv Chronic Dis | 2023 | https://conductscience.org/library/papers/36969501 | PubMed |
| 36658588 | How we treat primary immune thrombocytopenia in adults. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/36658588 | PubMed |
| 35708136 | Diagnosis of immune thrombocytopenia, including secondary forms, and selection of second-line treatment. | Haematologica | 2022 | https://conductscience.org/library/papers/35708136 | PubMed |
| 35401500 | Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center. | Front Immunol | 2022 | https://conductscience.org/library/papers/35401500 | PubMed |
| 34628650 | Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. | Med J Aust | 2022 | https://conductscience.org/library/papers/34628650 | PubMed |
| 34572358 | Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary? | Biomedicines | 2021 | https://conductscience.org/library/papers/34572358 | PubMed |
| 33801294 | Emerging Therapies in Immune Thrombocytopenia. | J Clin Med | 2021 | https://conductscience.org/library/papers/33801294 | PubMed |
| 32384539 | Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. | Blood Adv | 2020 | https://conductscience.org/library/papers/32384539 | PubMed |
| 32185250 | Lupus thrombocytopenia: pathogenesis and therapeutic implications. | Mediterr J Rheumatol | 2017 | https://conductscience.org/library/papers/32185250 | PubMed |
| 32135622 | [Interpretation of the updated international consensus report on the investigation and management of adult primary immune thrombocytopenia (version 2019)]. | Zhonghua Xue Ye Xue Za Zhi | 2020 | https://conductscience.org/library/papers/32135622 | PubMed |
| 31770441 | Updated international consensus report on the investigation and management of primary immune thrombocytopenia. | Blood Adv | 2019 | https://conductscience.org/library/papers/31770441 | PubMed |
Drugs8
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| HYDROXYCHLOROQUINE | CHEMBL1535 | Results | 5 | https://conductscience.org/library/drugs/CHEMBL1535 | ChEMBL |
| AZATHIOPRINE | CHEMBL1542 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL1542 | ChEMBL |
| DEXAMETHASONE | CHEMBL384467 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL384467 | ChEMBL |
| ELTROMBOPAG | CHEMBL461101 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL461101 | ChEMBL |
| PREDNISONE | CHEMBL635 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL635 | ChEMBL |
| METHYLPREDNISOLONE | CHEMBL650 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL650 | ChEMBL |
| VINCRISTINE | CHEMBL90555 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL90555 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24254965
GET https://conductscience.org/api/papers/v1/24254965/cited_by?page=2